The specter of generic rivalry has repeatedly loomed above copyright’s blockbuster drug, Sildenafil, triggering questions about the prospects of connected drug portfolios. While initial periods saw significant profits, the patent expiration has created the path for cheaper substitutes, likely reducing revenue and posing a genuine risk for stakeho